pharmaceutical investing Johnson & Johnson announces TREMFYA® is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis study 25 September
pharmaceutical investing Single infusion of CARVYKTI® delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma 25 September
pharmaceutical investing DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026 22 September
